UK Health Secretary James Murray has stated he remains "uneasy" about a controversial National Health Service (NHS) trial involving puberty blockers for children, while Members of Parliament (MPs) have voiced criticism regarding the insufficient support available for individuals who detransition.
During a parliamentary session, Murray acknowledged a "lack of clinical evidence" concerning the risks and benefits of these drugs. However, he indicated that the trial should proceed with caution and under rigorous scrutiny. He described the matter as "difficult" and "uncomfortable," admitting his personal unease.
Despite his reservations, Murray emphasized that the government must adhere to clinical advice. He sought assurances regarding safeguards before endorsing the trial for children as young as 11. The protocol for the trial includes provisions for automatically withdrawing participants and offers monitoring and clinical interventions.
The trial, known as the Pathways trial, aims to investigate the side effects of puberty blockers. It was recommended by the Cass Review, which examined the treatment of transgender youth. Approximately 226 children are expected to participate in the trial, receiving drugs that temporarily halt the natural progression of puberty. The trial was previously halted in February due to safety concerns raised by the Medicines and Healthcare products Regulatory Agency (MHRA), which initially suggested restricting it to individuals aged 14 and over. However, recruitment is set to resume from August 1, following an agreement on the lower age threshold.
The trial has faced opposition from various groups and public figures. Helen Joyce, director of advocacy at Sex Matters, criticized the trial, suggesting that there is already considerable knowledge about the risks associated with puberty blockers. She urged the health secretary to halt the trial, calling it a potentially "shameful episode in the history of medicine."
Separately, MP Gregory Stafford highlighted the challenges faced by individuals who detransition. He pointed out that the Cass Review had called for dedicated support for this group, yet a nationally commissioned NHS detransition pathway remains unavailable two years later. Stafford also raised the case of a 23-year-old detransitioner with complex needs who underwent surgery despite not fully passing capacity tests. Sir Jim Mackey, chief executive of NHS England, requested details about this case for further investigation.
Campaigners opposing the trial plan to seek a judicial review to halt what they deem an "unethical experiment." They argue that the MHRA has yielded to "gender ideology." Notable figures, including author J.K. Rowling, have publicly opposed the trial, describing it as an "unethical experiment on children who can’t give meaningful consent." Conservative leader Kemi Badenoch has stated her party's intention to attempt to ban the trial through amendments to the Health Bill.